Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing.
Proceeds from the financing will be used to further expand production capacity in its St. Peters, Mo. manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform.